Multi-institutional phase i study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer

Radiotherapy and Oncology

Volumn 113, Issue 1, 2014, Pages 35-40

  Konski, Andre ^a   Meyer, Joshua E ^b   Joiner, Michael ^a   Hall, Michael J ^b   Philip, Philip ^a   Shields, Anthony ^a   McSpadden, Erin ^a   Choi, Minsig ^a   Adaire, Beth ^b   Duncan, Gail ^b   Meropol, Neal J ^c   Cescon, Terrence P ^d   Cohen, Steven J ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d READING HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Pancreatic cancer; Radiation sensitization of chemotherapy; Ultra fractionated radiotherapy

Indexed keywords

ERLOTINIB; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; QUINAZOLINE DERIVATIVE;

ABDOMINAL RADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; ELECTROCORTICOGRAPHY; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HYPOALBUMINEMIA; INTESTINE PERFORATION; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; PANCREAS CANCER; PANCREAS METASTASIS; PERFORATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RASH; ULTRA FRACTIONATED RADIOTHERAPY; VOMITING; WEIGHT REDUCTION; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; RADIATION DOSE FRACTIONATION; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE FRACTIONATION; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PANCREATIC NEOPLASMS; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84922697155     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2014.08.014     Document Type: Article

References (34)

1. Marples B, Joiner MC. The response of Chinese hamster V79 cells to low radiation doses: evidence of enhanced sensitivity of the whole cell population. Radiat Res 1993; 133: 41-51.
2. Marples B, Wouters BG, Collis SJ, et al. Low-dose hyper-radiosensitivity: a consequence of ineffective cell cycle arrest of radiation-damaged G2-phase cells. Radiat Res 2004; 161: 247-55.
3. Krueger SA, Joiner MC, Weinfeld M, et al. Role of apoptosis in low-dose hyperradiosensitivity. Radiat Res 2007; 167: 260-7.
4. Mitchell CR, Folkard M, Joiner MC. Effects of exposure to low-dose-rate (60)co gamma rays on human tumor cells in vitro. Radiat Res 2002; 158: 311-8.
5. Mitchell CR, Joiner MC. Effect of subsequent acute-dose irradiation on cell survival in vitro following low dose-rate exposures. Int J Radiat Biol 2002; 78: 981-90.
6. Harney J, Shah N, Short S, et al. The evaluation of low dose hyperradiosensitivity in normal human skin. Radiother Oncol 2004; 70: 319-29.
7. Harney J, Short SC, Shah N, et al. Low dose hyper-radiosensitivity in metastatic tumors. Int J Radiat Oncol Biol Phys 2004; 59: 1190-5.
8. Pulkkanen K, Lahtinen T, Lehtimaki A, et al. Effective palliation without normal tissue toxicity using low-dose ultrafractionated re-irradiation for tumor recurrence after radical or adjuvant radiotherapy. Acta Oncol 2007; 46: 1037-41.
9. Krause M, Hessel F, Wohlfarth J, et al. Ultrafractionation in A7 human malignant glioma in nude mice. Int J Radiat Biol 2003; 79: 377-83.
10. Krause M, Joiner M, Baumann M. Ultrafractionation in human malignant glioma xenografts. Int J Cancer 2003; 107: 333. author reply 334.
11. Krause M, Prager J, Wohlfarth J, et al. Ultrafractionation does not improve the results of radiotherapy in radioresistant murine DDL1 lymphoma. Strahlenther Onkol 2005; 181: 540-4.
12. Krause M, Wohlfarth J, Georgi B, et al. Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo. Int J Radiat Biol 2005; 81: 751-8.
13. Joiner MC, Marples B, Johns H. The response of tissues to very low doses per fraction: a reflection of induced repair? Recent Results Cancer Res 1993; 130: 27-40.
14. Balcer-Kubiczek EK, Attarpour M, Wang JZ, et al. The effect of docetaxel (taxotere) on human gastric cancer cells exhibiting low-dose radiation hypersensitivity. Clin Med Oncol 2008; 2: 301-11.
15. Dey S, Spring PM, Arnold S, et al. Low-dose fractionated radiation potentiates the effects of paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. Clin Cancer Res 2003; 9: 1557-65.
16. Enns L, Bogen KT, Wizniak J, et al. Low-dose radiation hypersensitivity is associated with p53-dependent apoptosis. Mol Cancer Res 2004; 2: 557-66.
17. Arnold SM, Regine WF, Ahmed MM, et al. Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm. Int J Radiat Oncol Biol Phys 2004; 58: 1411-7.
18. Demaria S, Bhardwaj N, McBride WH, et al. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005; 63: 655-66.
19. Finkelstein SE, Fishman M. Clinical opportunities in combining immunotherapy with radiation therapy. Front Oncol 2012; 2: 169.
20. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 2013; 105: 256-65.
21. Kalbasi A, June CH, Haas N, et al. Radiation and immunotherapy: a synergistic combination. J Clin Invest 2013; 123: 2756-63.
22. Klug F, Prakash H, Huber PE, et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 2013; 24: 589-602.
23. Rodel F, Frey B, Multhoff G, Gaipl U. Contributions of the immune system to bystander and non-targeted effects of ionizing radiation. Cancer Lett 2014, in press.
24. Regine WF, Hanna N, Garofalo MC, et al. Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm. Int J Radiat Oncol Biol Phys 2007; 68: 172-7.
25. Sharma NK, Pandya N, Wong R, Herman J, Hanna NN, Laheru DA, et al. Low dose upper abdominal radiation therapy (LD-UART) potentiates gemcitabine in patients with advanced, unresectable pancreatic cancer (PC): final results from a phase ii multi-institutional study. Int J Radiat BIol Phys 2010; 78: S103.
26. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-6.
27. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
28. Burris 3rd HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13.
29. Inal A, Ciltas A, Yildiz R, et al. Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective analysis of an Anatolian Society of Medical Oncology multicenter study. Asian Pac J Cancer Prev 2012; 13: 1841-4.
30. Wo JY, Mamon HJ, Ferrone CR, et al. Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. Radiother Oncol 2014; 110: 160-4.
31. Terashima K, Demizu Y, Hashimoto N, et al. A phase I/II study of gemcitabineconcurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis. Radiother Oncol 2012; 103: 25-31.
32. Mori S, Shinoto M, Yamada S. Four-dimensional treatment planning in layerstacking boost irradiation for carbon-ion pancreatic therapy. Radiother Oncol 2014; 111: 258-63.
33. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-25.
34. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-703.